INTRODUCTION
Cancer in bone tissue is typically the result of tumor metastases from a distant site, and cancers having the highest prevalence of bone metastases (lung, prostate, and breast) are the most frequently diagnosed cancers worldwide (1, 2) . In the United States, in 2013, the estimated number of new cases of cancer in the lung (228, 190) , prostate (238,590) and breast (234,580) (3), combined with the known prevalence of bone metastasis in lung, prostate, and breast cancer (<36%, <90%, 65-75%, respectively)(4), results in the estimate that 460,000 new cases of bone metastases will be diagnosed. Once cancer metastasis to bone (CMB) occurs, it is usually incurable (unless the metastases are limited to very few sites). However, advances in cancer treatments continue to dramatically increase survival rates, thus patients with metastatic disease and suffering with malignant skeletal pain are living years to decades beyond their initial cancer diagnosis.
Maintenance of the functional status of patients with CMB requires proactive management as CMB can cause excruciating bone pain, pathologic fractures, spinal cord and nerve compression syndromes, weight loss, derangements of calcium and phosphate homeostasis and decline in the ability to load and use tumor-bearing bones cannot be viewed individually but rather as interactive events ultimately contributing to increased morbidity, mortality, and diminished quality of life (2, 5) .
In the past decade, progress has been made in understanding what drives CMB.
Bisphosphonates and the RANK ligand inhibitor, Denosumab, have been approved for treatment of both pain and preventing bone fracture (6, 7) . A therapy showing promise in blocking pain induced by CMB and non-malignant skeletal pain is inhibition of nerve growth factor (NGF) and its primary receptor, tyrosine kinase receptor type 1 (TrkA) (8) (9) (10) . In breast, sarcoma, and prostate mouse models of CMB, anti-NGF significantly attenuates bone cancer pain (11) (12) (13) (14) (15) . Additionally, in humans, anti-NGF attenuates moderate-to-severe skeletal pain due to osteoarthritis or low back pain (16, 17) .
While animal and human studies suggest that blockade of NGF/TrkA effectively alleviates malignant and non-malignant skeletal pain, most efforts at developing novel therapies to block or sequester Author Manuscript Published OnlineFirst on October 6, 2014; DOI: 10.1158/0008-5472.CAN- NGF or TrkA were not initially developed to treat skeletal pain but rather to block/attenuate tumor growth and metastasis. Extensive in vitro studies show that NGF and/or TrkA drive the growth and metastasis of breast, ovarian, lung, pancreas, and prostate tumor cells (18) (19) (20) . Moreover, in vivo studies show that anti-NGF inhibits ethylnitrosourea-induced carcinogenesis in mice and rats (21) , and either anti-NGF or siRNA against NGF inhibits breast cancer tumor growth and metastasis in a mouse xenograft model (22) .
In the present study we directly address these CMB patient issues by using a primarily osteolytic model of bone cancer which drives tumor-induced bone loss, bone fracture, loss of the use of the tumor-bearing limb, and weight loss. We explore whether early administration of anti-NGF can attenuate these pathological features. In addition we have modified and refined our bone disease progression and behavioral endpoints to more closely mirror endpoints used in human clinical studies in patients with CMB. (26) . Upon thaw, GFP-transfected NCTC 2472 cells were cultured according to ATCC recommendations, passaged for at least three, but not more than 20 passages (less than three months), and verified mycoplasma-free before injection into mice. Additional information included in Supplemental Material. Surgery: Injection of NCTC 2472 cells directly into the intramedullary space of the mouse femur was as previously described (13, (27) (28) (29) (30) (31) (32) (33) . To prevent the patella from becoming displaced postarthrotomy, muscles were secured back in position using a horizontal mattress suture. In addition, after surgery, animals were individually housed and allowed to recover for one week before being handled for behavioral and radiological assessment. Additional information included in Supplemental Material.
Anti-NGF Treatment:
The anti-NGF sequestering antibody (mAb911), kindly provided by Dr. David Shelton (Rinat/Pfizer, San Francisco, CA), blocks the binding of NGF to both TrkA (tyrosine kinase receptor type 1, NTRK1) and p75 (neurotrophin receptor, LNGFR), and inhibits TrkA autophosphorylation (34) . Anti-NGF has no effect on healthy bone (11) (12) (13) (14) (35) (36) (37) , its plasma half-life is five to six days in the mouse, and it does not appreciably cross the blood-brain barrier (38) . In this study, the dose used (10 mg/kg, i.p.) was based on previous studies (11) , and it was delivered starting at Day 7 post-cancer cell injection, and every five days thereafter.
Assessment of bone cancer disease progression and pain
Mice were assessed for bone cancer disease progression, functional status, and both spontaneous and movement-evoked pain, to measure endpoints that are clinically relevant to the patient with bone cancer (2, 9) . Behavioral testing was performed on the same days as radiological assessment to enable comparison between pain behavior and bone destruction. Each method of behavioral assessment was performed by the same experimenter who was blinded to the drug treatments. Radiology: High resolution X-ray images of cancer or vehicle-injected femurs were obtained several days before surgery (baseline), and immediately following weekly behavioral assessments, using a Faxitron MX-20 digital cabinet X-ray system (Faxitron/Bioptics, Wheeling, IL). Mice were lightly anesthetized with ketamine/xylazine (0.005 ml/g, 50 mg/10 kg, s.c.) to enable consistent placement of the animal for radiological assessment. Faxitron settings were optimized for radiological assessment of cortical or trabecular bone destruction. Animals were excluded from the study if a patella displacement was identified through radiography (see Supplemental Material, Fig. 1 ).
Bone Scoring: To quantify the extent of bone destruction, and to separately analyze disease progression at the distal and proximal aspects of tumor-bearing femora, a 10-point bone scoring method was used in which the distal and proximal halves of each femur were scored separately on a previously validated scale of 0 to 5 (28, 33) , and then the scores for each femur half were summed (maximum possible score of 10). For each femoral aspect, bone scores were defined as: 0, normal bone with no signs of destruction; 1, small pits (1-3 in number) of bone destruction; 2, increased pitted appearance (4-6 in number) and loss of medullary bone; 3, loss of medullary bone and erosion of cortical bone; 4, full thickness unicortical bone loss; 5, full thickness bicortical bone loss and displaced skeletal fracture (Fig. 1) .
Time-to-fracture: The radiographic endpoint "time-to-fracture" was defined as the time (day) following surgery when a fracture was identified through radiography.
Spontaneous nocifensive behavior:
Mice were placed in small raised Plexiglas chambers (11.5 x 6.8 x 7.5 cm) with a wire grid floor, acclimated for 30 min (until cage exploration and major grooming activities ceased), and then their movements were videotaped from below using Sony Handycam DCR-SR68 cameras. Time spent in "nocifensive" behavior was assessed during a 5-min observation 
Exclusion criteria
Animals were observed daily, and criteria for exclusion from the study (and euthanasia) included: rapid weight loss (>20% in one week), patella displacement, lack of intra-femoral cancer cell growth, extra-femoral cancer cell growth, prolonged digestive abnormalities (e.g., diarrhea or vomiting for over three days), severe ulcerative dermatitis or infected tumors, and paralysis. 
Statistical analysis
One-way ANOVA was used to compare behavioral and radiological bone scoring results between experimental groups. Significance level was set at P < 0.05.
Results

Characterization of bone cancer pain model
Experimental investigation in our optimized model involved first baseline behavioral assessment and X-ray analysis of naïve mice, followed by selection of animals with comparable values and their random assignment to treatment groups (vehicle or therapy). To monitor disease progression, high-resolution radiographs of the mouse femur were taken at various time points postsurgery. Radiological evidence of bone destruction presents as radiolucent areas, typically observed in the distal and proximal aspects of the femur at early time points of disease progression. As time and disease progress, multiple focal radiolucencies are accompanied by loss of medullary bone, erosion of cortical bone, and ultimately, fracture ( Day 18 post-surgery, at which time it was approximately eight-fold higher than that at Day 7 postsurgery. After Day 18 post-surgery, nocifensive behavior in NCTC 2472-injected mice steadily increased, although at a less rapid pace, and was approximately ten times that of Day 7 post-surgery at the end of the study (Day 30) . Collectively, these data demonstrated that our bone cancer model enabled the differentiation between surgical and cancer cell-induced bone pain, thereby providing an accurate assessment of cancer cell-induced pain and the efficacy of therapies targeted specifically to attenuate cancer-induced bone pain.
To demonstrate the importance of location of cancer cell growth in the development of pain behaviors, we included in our study a group of "muscle-injected" animals wherein NCTC 2472 cells were injected directly into the muscle adjacent to the femur. Despite the development of large tumor volumes, "muscle-injected" animals did not exhibit nocifensive behavior (Fig. 3) .
Anti-NGF therapy attenuates sarcoma-induced bone destruction
To determine the effect of anti-NGF on NCTC 2472-induced bone destruction, mice were administered injections of either vehicle (phosphate-buffered saline, PBS) or anti-NGF in PBS (10 mg/kg, i.p.). Anti-NGF therapy was initiated at Day 7 post-surgery, and repeated every five days. At Fig 4B) . The importance of the attenuating effect of anti-NGF on bone destruction in terms of overall functionality was demonstrated by the fact that at Day 28 post-NCTC 2472 injection, the percent of anti-NGFtreated mice with evidence of fracture was half that of vehicle-treated mice (Fig. 4C) .
Anti-NGF therapy attenuates bone cancer-induced weight loss
Weight maintenance in cancer patients remains an important clinical challenge. In our preclinical model, a loss of 20% of baseline weight was a severe physiological event requiring removal from the study and euthanasia. Our data show that at Day 28 post-cancer cell injection, when there was significant disease progression and bone destruction, mice treated with anti-NGF therapy had only lost ~2% of their baseline weight, whereas vehicle-treated mice had lost ~6% of their baseline weight (Fig. 5) .
Anti-NGF attenuates spontaneous and movement-evoked bone cancer pain behaviors
To determine the efficacy of anti-NGF in reducing bone pain in both early and late stage bone cancer disease, spontaneous nocifensive behavior exhibited by vehicle-and anti-NGF-treated mice was analyzed with respect to bone score (Fig. 6A) . Mouse movements defined as "nocifensive" were full guarding, reducing weight-bearing and abnormal grooming of the affected limb, and also sporadic hopping using the non-affected limb (see Methods, Supplemental Material videos). Spontaneous nocifensive behavior associated with a bone score of 0 was minimal for both treatment groups (approximately 25-30 sec, 8-10% of the 300-second assessment period), and was reflective of the pain experienced the week following cancer cell injection due to the surgical procedure. This pain was not NCTC 2472-induced bone cancer pain (Fig. 2, 4B ). The ability of anti-NGF treatment to reduce pain-related behaviors in both early and late stage bone cancer disease was also revealed by analysis of dynamic weight bearing and limb use in vehicle-and anti-NGF-treated mice with respect to time (day) following cancer-cell injection (Fig. 6   C,D) . Measurement of dynamic weight bearing in the mouse is equivalent to the human clinical measure of the ability to load the tumor-bearing bone. In vehicle-treated mice, the weight borne for the tumor-bearing limb progressively decreased over the course of the study; at Day 28 post-cancer cell injection the ability of the tumor-bearing hind limb to bear weight had been reduced by over 70% (Fig. 6C) . In contrast, anti-NGF treatment reduced bone cancer-induced pain enough that the animal was capable of preserving the ability of the tumor-bearing hind limb to bear weight. At Days 21 and (Fig. 6D) . 
DISCUSSION
In the present study, we used a mouse model of sarcoma-induced bone cancer and showed that early treatment with anti-NGF reduced tumor-induced bone destruction, delayed time-to-fracture, and increased the use of the tumor-bearing limb. Additionally, as suggested in previous studies in animal models of osteoarthritis (39) and head/neck cancer (40) , early blockade of NGF also reduced weight loss in animals with bone cancer. In terms of the extent and time course of pain relief, blockade of NGF reduced bone cancer pain by 40-70% depending on the pain measure being assessed, and this analgesic effect was maintained even in animals with late stage disease.
NGF and bone cancer disease progression
In the current study, NGF blockade delayed bone cancer disease progression; measured by time-to-fracture, tumor-induced bone destruction, and tumor-bearing limb use. What the specific mechanisms that maintain the integrity and use of bone remain unclear, but previous data in both older individuals and those with CMB have suggested that exercise and loading of the bone promotes bone health. Previous studies in human clinical trials in patients with moderate-to-severe osteoarthritis pain showed that anti-NGF attenuated this pain by 40-50%. However, within this group a small but significant number of patients receiving the highest dose of anti-NGF and naproxen required earlier-than-expected joint replacement. Whether this earlier-than-expected joint replacement was caused by overuse of the arthritic joints due to the robust pain relief provided by anti-NGF, or was a direct effect of blocking NGF on the maintenance and formation of adult bone remains unknown (10) . However, in patients with CMB, fracture of the tumor-bearing bone is a highly undesirable event as active tumor-induced bone destruction makes stabilization and repair of the fractured bone problematic. These data extend previous data showing that it is not size, but rather location and specific nerve innervation, that influences tumor-induced pain (8, 9, 11, 42, 43 
Early vs. late administration of anti-NGF following cancer metastasis to bone
Current clinical trials are examining or considering examining the blockade of NGF/TrkA in terms of being an analgesic and not a disease modifying agent. However, the present data suggests that if anti-NGF can reduce tumor-induced bone destruction, time-to-fracture, weight loss, and CMB pain, and also maintain the functional status of patients, then early rather than late administration of anti-NGF following the initial diagnosis of CMB appears warranted. Currently, following diagnosis of CMB, where the initial diagnosis of CMB is frequently mild-to-moderate bone pain, patients usually are put on the WHO "analgesic ladder" for treatment of cancer pain which consists of NSAIDs alone, then NSAIDs + weak opiate, and finally NSAIDs + strong opiate. However, NSAIDs inhibit bone formation, and opiates have numerous side effects including nausea, dizziness, constipation and somnolence (9) . In contrast, blockade of NGF or TrkA has remarkable efficacy in attenuating skeletal pain, and a total of 11,000 patients that received anti-NGF for non-metastatic skeletal pain had relatively few side effects (16) .
One major concern with administering anti-NGF to humans with late stage disease bone cancer pain is that the patient typically will already be on NSAIDs + strong opiate, making it difficult to discern even an analgesic effect. However, in clinical trials if anti-NGF is given early (immediately upon diagnosis of CMB), and anti-NGF does have the positive effects on maintaining bone health, preventing bone fractures and weight loss, and reducing skeletal pain, early therapy with anti-NGF may significantly help in maintaining the functional status and quality of life of the patient. This would be especially true in a population of breast cancer patients who are young women (20-44 years old), and in the early or midstage of their careers and/or raising a family. As survival times of these young women with metastatic breast cancer have significantly increased (44) , an important and unmet objective is to maintain their functional status and quality of life without the unwanted side effects of currently available therapies. 
Pre-clinical vs. clinical measures of bone cancer disease progression and pain
Essential to the translational success of an emerging therapy is its validation in a pre-clinical animal model that incorporates endpoints directly translatable to those that can be used in human clinical trials. In the clinic, commonly-measured endpoints for bone cancer disease progression and functional status include radiological assessment of bone destruction and time-to-fracture (5), weight loss (45), evaluation of gait and weight-bearing (46, 47) , and pain (48) (49) (50) . As illustrated in Fig. 7 , preclinical (mouse) measures incorporated in the present study to monitor disease progression, functional status, and pain closely mirror the human clinical measures used.
Limitations and conclusions of the study
To provide a clinically-relevant animal model of bone cancer pain, we originally developed and have recently optimized a mouse model in which mouse NCTC 2472 osteolytic sarcoma-producing cells are injected directly into the intramedullary space of the femur, following which the injection site is sealed with bone cement (13, (27) (28) (29) (30) (31) (32) (33) Additional limitations of the current study are that the in vivo analysis was only performed using one tumor cell line, and that a single species and gender was used in the present study. However, previous work from our laboratory has investigated the effect of anti-NGF on bone cancer pain using implantation of breast cancer and prostate cancer cells (11, 12, 14, 15) . These previous studies and the current study show anti-NGF effectively attenuates bone pain in all three mouse models of bone cancer pain.
Concerning the potential for observer bias in the analysis of pain behavior, we believe that due to the preventive measures taken in this work we have precluded, as much as humanly possible, the occurrence of subjective and biased pain measurements. Personnel measuring pain behaviors and analyzing x-rays were scrupulously blinded to the therapy treatments. Parameters for spontaneous nocifensive pain and limb use were specifically delineated prior to the start of this work, and 
